Prescient Therapeutics (ASX: PTX) Launches SPP to Boost Cancer Therapy Trials | All Ordinaries
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.
Prescient Therapeutics opens Share Purchase Plan to support PTX-100 clinical development.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is targeting A$7 million through a Share Purchase Plan (SPP) to...
Clinical stage biotech Prescient Therapeutics is developing new therapies for cancers of unmet need, aggressive...
In this HotCopper Capital Compass interview, Prescient Therapeutics (ASX:PTX) CEO James McDonnell discusses the company’s progress with PTX-100, a...
PTX-100 targets high-mortality cancers linked to RAS mutations.
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) is aiming to establish new frontiers in cancer care, with...
The first patient has been dosed in Prescient Therapeutics Phase 2a clinical trial of PTX-100...
Prescient Therapeutics (ASX: PTX) begins Phase 2A trial of PTX-100 for rare lymphoma, drug shows...
Prescient Therapeutics (ASX: PTX) earlier this week began its Phase 2A clinical trial of PTX-100...
Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase...

This investor centre was built by Reach Markets
©2026 Reach Markets
To stay up to date with Prescient Therapeutics news and events, please register your details.